FDA Approves New BTK-Targeted Therapeutic for Non-Hodgkin Lymphoma
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults...
Tag: FDA
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a revolutionary new type of immunotherapy...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just...
Last week, the U.S. Food and Drug Administration (FDA) increased the number of types of cancer for which immunotherapeutics...
The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last...
This week’s excitement surrounding the groundbreaking U.S. Food and Drug Administration (FDA) approval of the CAR T–cell therapy tisagenlecleucel...
Yesterday marked a much anticipated milestone for the oncology community: The U.S. Food and Drug Administration (FDA) announced the...
This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx)...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...